TCC 1727
Alternative Names: TCC-1727Latest Information Update: 18 Aug 2023
At a glance
- Originator Beijing Tide Pharmaceutical
- Class Antineoplastics; Small molecules
- Mechanism of Action ATR protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 08 Aug 2023 TCC 1727 is available for licensing as of 08 Aug 2023. https://en.tidepharm.com/hzgy (Tide Pharmaceuticals Website, Aug 2023)
- 02 Aug 2023 Preclinical trials in Solid tumours in China (PO) before August 2023 (NCT05970016)
- 01 Aug 2023 Beijing Tide Pharmaceutical plans a phase I/II trial for Solid tumors (Late-stage disease) in China (PO) in August 2023 (NCT05970016)